Why Valeant Pharmaceuticals Intl Inc. Is the Best Contrarian Pick for 2017

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is a newly minted value stock, which offers an interesting entry point for long-term investors. Strong cash flows from operations coupled with a new long-term growth strategy make this company a buy.

| More on:
The Motley Fool

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The worst may be over for Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), a once-juggernaut and Canadian pharma gem. A new strategy has been proposed by recently hired CEO Joseph C. Papa–one which focuses on core business fundamentals and driving revenue through the company’s exceptionally strong pipeline of new drugs, which will be brought to market over the next year.

First, let’s start off with what got Valeant in this mess and the move to what Mr. Papa is doing to fix the company.

Why did Valeant crash?

Valeant has seen its share price plummet by over 90% since mid-2015. A number of factors are at play with the company’s share price drop.

The company’s previous aggressive growth strategy, implemented by former CEO Michael Pearson, involved focusing on the distribution of drugs and growing the company’s pipeline through acquisition rather than R&D. This strategy involved buying companies with products that were “under-priced,” and Valeant would follow by raising drug prices on average by 66% to boost revenues and justify the acquisitions.

An inquiry into the drug-price increases was brought to light by former Democratic presidential candidate Bernie Sanders and 18 Democratic leaders, leading to a hearing before the House Committee on Oversight and Government Reform and scrutiny from a number of analysts.

Subsequently, the company’s distribution platforms (specifically Philidor, a specialty pharmacy chain connected with Valeant) were exposed for potential fraud by famous (or infamous) short-seller Andrew Left at Citron Research. Left publicly accused the company of accounting fraud, comparing it to Enron, and announced his short position accordingly. The company relationship to Philidor (including the option to purchase the pharmacy chain) was not disclosed in filings leading to further inquiry and investor scrutiny.

Valeant later announced that it indeed paid $100 million to purchase Philidor and would cut ties with the pharmacy chain, divesting its holdings.

The company has since been plagued with legal scrutiny, and the majority of traditional long-term investors have pulled out of Valeant, leading to large downward swings in the company’s stock price.

Where is Valeant today?

The company reports revenue and earnings via a “non-GAAP” method, adjusting figures upward to account for large reconciliations related to acquisitions or divestitures, making the financial statements especially hard to digest.

That said, the company’s stock is currently trading at 1.4 times book value and is no longer seen as a “growth gem.” A long-term investor such as myself looks at Valeant as a newly minted value opportunity should the company grow revenues organically through its existing pipeline of products.

CEO Joesph Papa announced the company’s turnaround strategy, which relies heavily on R&D of the company’s current pipeline of 15 drugs which will be brought to market over the next year. This strategy is markedly different from Pearson’s strategy and needs to be scrutinized heavily over the short term. If the company is indeed willing and able to follow through on this strategy, the company will very likely be able to move toward hitting its forecasted forward EPS of $7.70 per share.

Free cash flows from operations (CFFO) are strong with second quarter CFFO increasing 9% from Q2 2015. If the company is set on executing this long-term turnaround plan, most of these cash flows will be used to pay down debt and further divestitures are likely. The long-term investor will need to assess if these asset sales will be able to assist in growing the profitability of core operating assets. For the time being, the situation looks promising.

Pershing Square CEO and activist investor Bill Ackman has publicly stood by Valeant, announcing his support for the company long term. His reputation for driving company profitability through cutting costs and increasing margins brought him to Valeant.

The company’s current situation makes the stock attractive to me for the following reasons:

  • New management and a long-term strategy have shown some short-term success and will likely continue to bring improved profitability and earnings over the long run.
  • Investors such as Bill Ackman, who have shown long-term attachment to Valeant, provide me with assurance the company’s turnaround plan is likely to succeed.

The price to book value of assets at 1.4 times makes the company a steal at current prices. I will be assessing the stock in the short term and any dips toward P/BV of one would make this stock a guaranteed buy. Buying the stock for around what the assets are worth provides a significant moat to a value investor.

Should you invest $1,000 in Bausch Health Companies right now?

Before you buy stock in Bausch Health Companies, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Bausch Health Companies wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $20,697.16!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 29 percentage points since 2013*.

See the Top Stocks * Returns as of 3/20/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Investing

Medicinal research is conducted on cannabis.
Tech Stocks

Buy the Dip, Eh? 3 Canadian Stocks to Scoop Up During This Correction

Looking for value in a correction? Now could be the time to pick up these three Canadian stocks.

Read more »

dividend growth for passive income
Stocks for Beginners

The Smartest Growth Stock to Buy With $5,000 Right Now

Aritzia’s (TSX:ATZ) solid fundamentals with rising U.S. brand awareness and consistent execution across both physical and digital channels make it…

Read more »

A worker drinks out of a mug in an office.
Dividend Stocks

With Stocks Down in 2025, Should You Buy the Dip?

Should you buy the dip? In this article, I explore that question, ultimately concluding that it depends on what you…

Read more »

oil pump jack under night sky
Energy Stocks

Where Will Suncor Stock Be in 3 Years?

Suncor is performing exceptionally well, and after a record-breaking 2024, it stands well positioned to extend this momentum into 2025.

Read more »

a man relaxes with his feet on a pile of books
Dividend Stocks

Navigating the Correction: A Smart Investor’s Guide to Canadian Value Plays

Are you looking for more value from you Canadian stocks? Check out these winners on the TSX today.

Read more »

Investor wonders if it's safe to buy stocks now
Investing

Waste Connections: Buy, Sell, or Hold in 2025?

Waste Connections (TSX:WCN) stock isn't cheap, but it's still looking attractive at current prices.

Read more »

Man data analyze
Investing

Stocks on the Move That Are Still Deals Today

Magna International (TSX:MG) has been choppy but shares look cheap here.

Read more »

a sign flashes global stock data
Stock Market

My Zaniest Stock Market Predictions for 2025 

Understand the economic prediction for 2025 and the potential rebound in sectors hit by tariffs. Read more for analysis.

Read more »